ClinicalTrials.gg
CompletedNCT04757376Updated Jun 14, 2024Results posted

A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis

A Phase 3 interventional study of CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis, sponsored by Celltrion. Completed at 20 sites in 4 countries. Open to female participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-06-14.

Sponsored by Celltrion · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
479
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.

Enrollment
8th of 64
479 · median 90
Started
2021
with 3 others
Phase 3
24 of 64
2 open now
Registered
51st of 64
by date

Among the 64 studies testing denosumab in Osteoporosis, this one is the 8th largest by enrollment, is one of 4 that started in 2021, is one of 24 in phase 3, and was the 51st registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 50 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing denosumab in Osteoporosis, or all of them as a file.
02

Study summary

This study is a Double-blind, Randomized, Active-controlled, Phase 3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of CT-P41 and US-licensed Prolia in Postmenopausal Women with Osteoporosis

Read the detailed description

This is a double-blind, randomized, active-controlled, Phase 3 study to evaluate the efficacy, PK, PD, and safety including immunogenicity of CT-P41 compared with US-licensed Prolia in postmenopausal women with osteoporosis. All patients will also receive daily supplementation containing at least 1,000 mg of elemental calcium and at least 400 IU vitamin D from randomization to EOS visit and the data will be collected via patient's diary.

03

Conditions studied

  • Postmenopausal Women With Osteoporosis

Browse trials for

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women, 50 to 80 years of age, both inclusive.
  2. Body weight between 40.0 and 99.9 kg, both inclusive, when rounded to the nearest tenth.
  3. Bone mineral density T-score ≤ - 2.5 and ≥ - 4.0 at the lumbar spine (L1 to L4) as assessed by the central imaging vendor based on dual-energy X-ray absorptiometry(DXA) scan.
  4. Patients must have at least 3 vertebrae considered evaluable at the lumbar spine (L1 to L4) and at least 1 hip considered evaluable by DXA scan assessed by the central imaging vendor. Patients with unilateral metal in hips that would be allowed for the other side of 1 evaluable hip are included.
  5. Patient with albumin-adjusted total serum calcium ≥ 8.5 mg/dL (≥ 2.125 mmol/L) at Screening.

Exclusion criteria

Exclusion Criteria:

  1. Patient previously received denosumab, any other monoclonal antibodies, or biologic agents for osteoporosis
  2. Patient confirmed or suspected with infection of COVID-19 at Screening, or has contact with COVID-19 patient within 14 days from Screening
  3. Patient with history and/or presence of one severe or > 2 moderate vertebral fractures as determined by central reading of lateral spine X-ray
  4. Patient with history and/or presence of hip fracture
  5. Patient with history and/or presence of hyperparathyroidism or hypoparathyroidism, irrespective of current controlled or uncontrolled status
  6. Patient with current hyperthyroidism (unless well controlled on stable antithyroid therapy)
  7. Patient with current hypothyroidism (unless well controlled on stable thyroid replacement therapy)
  8. Patient with history and/or presence of bone disease and metabolic disease (except for osteoporosis) that may interfere with the interpretation of the results
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
479 participants (actual)

Study arms

  • Experimental
    CT-P41

    60 mg/mL single dose administration, Solution for injection in prefilled syringe(PFS)

    Biological: CT-P41

  • Active comparator
    US-licensed Prolia

    60 mg/mL single dose administration, Solution for injection in PFS

    Biological: US-licensed Prolia

Interventions

  • BiologicalCT-P41

    60 mg/mL single dose, Solution for injection in PFS

  • BiologicalUS-licensed Prolia

    60 mg/mL single dose, Solution for injection in PFS

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 52 - Full Analysis Set (FAS)

    Bone mineral density was assessed by dual-energy X-ray absorptiometry (DXA) and assessments of the lumbar spine (L1 to L4) were performed at a central imaging vendor. To evaluate the difference between 2 groups in the primary efficacy endpoint, the percent change from baseline in BMD for lumbar spine (L1 to L4) by DXA at Week 52 was analyzed using an analysis of covariance (ANCOVA) model coupled with multiple imputation assuming the data to be missing at random (MAR).

    Time frame: baseline (screening), Week 52 predose

Secondary outcomes

  1. Percent Change From Baseline in Lumbar Spine, Total Hip, and Femoral Neck BMD at Week 52 - FAS

    Bone mineral density was assessed by DXA and assessments of the lumbar spine (L1 to L4), total hip, and femoral neck were performed at a central imaging vendor.

    Time frame: baseline (screening), Week 52 predose

  2. Percent Change From Baseline in Lumbar Spine, Total Hip, and Femoral Neck BMD at Week 78 - FAS-TP II Subset

    Bone mineral density was assessed by DXA and assessments of the lumbar spine (L1 to L4), total hip, and femoral neck BMD were performed at a central imaging vendor.

    Time frame: baseline (screening), Week 78

  3. Incidence of New Vertebral, Nonvertebral, and Hip Fractures During TP I - FAS

    Efficacy analysis of new vertebral fractures included only vertebral fractures occurring from T4 to L4 and confirmed by the central imaging vendor. A new vertebral fracture was defined as an increase of ≥1 grade in any vertebra from T4 to L4 that was normal at screening. The nonvertebral fractures endpoint included fractures other than those of the vertebrae, excluding the skull, facial bones, mandible, metacarpals, and phalanges (fingers or toes) since they are not associated with decreased BMD, and excluded pathologic fractures and those associated with severe trauma acquired from a fall (from a height higher than a stool, chair, or first rung of a ladder) or otherwise. Only nonvertebral fractures confirmed by the central imaging vendor were included in the efficacy analysis. The fractures occurring at the site of femur neck, femur intertrochanter, or femur subtrochanter were considered as a hip fracture.

    Time frame: up to Week 52 predose

  4. Incidence of New Vertebral, Nonvertebral, and Hip Fractures During TP II - FAS-TP II Subset

    Efficacy analysis of new vertebral fractures included only vertebral fractures occurring from T4 to L4 and confirmed by the central imaging vendor. A new vertebral fracture was defined as an increase of ≥1 grade in any vertebra from T4 to L4 that was normal at screening. The nonvertebral fractures endpoint included fractures other than those of the vertebrae, excluding the skull, facial bones, mandible, metacarpals, and phalanges (fingers or toes) since they are not associated with decreased BMD, and excluded pathologic fractures and those associated with severe trauma acquired from a fall (from a height higher than a stool, chair, or first rung of a ladder) or otherwise. Only nonvertebral fractures confirmed by the central imaging vendor were included in the efficacy analysis. The fractures occurring at the site of femur neck, femur intertrochanter, or femur subtrochanter were considered as a hip fracture.

    Time frame: from Week 52 to Week 78

  5. Trough Serum Concentration (Ctrough) of Denosumab at Weeks 0 and 26 - Pharmacokinetic (PK) Set

    The Ctrough, a concentration before the next study drug administration, was calculated by non-compartmental analysis method from the concentration-time data. All serum concentrations below the lower limit of quantification (LLoQ) was set to 0 in the descriptive summaries of PK parameter estimation. In TP I, the Ctrough of denosumab at Weeks 0 and 26 was assessed as the serum concentration at Weeks 26 and 52 before the study drug administration, respectively.

    Time frame: Week 0 Day 1 predose, Week 26 predose

  6. Ctrough of Denosumab at Week 52 - PK-TP II Subset

    The Ctrough, a concentration before the next study drug administration, was calculated by non-compartmental analysis method from the concentration-time data. All serum concentrations below the LLoQ was set to 0 in the descriptive summaries of PK parameter estimation. In TP II, the Ctrough of denosumab at Week 52 was assessed as the serum concentration at Week 78.

    Time frame: Week 52

  7. Maximum Serum Concentration (Cmax) of Denosumab After First Dose - PK Set

    Cmax was calculated by non-compartmental analysis method from the concentration-time data. All serum concentrations below the LLoQ was set to 0 in the descriptive summaries of PK parameter estimation.

    Time frame: from baseline (Week 0 Day 1 predose) to Week 26 predose

  8. Percent Change From Baseline for Serum Concentration of Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) at Weeks 26 and 52 - Pharmacodynamic (PD) Set

    Serum concentration below the LLoQ was set to the LLoQ. The percent change from baseline for serum concentration at each visit was calculated as (\[Result at each visit - Result at Baseline\] / Result at Baseline) × 100.

    Time frame: Baseline (Week 0 Day 1 predose), Weeks 26 and 52 (predose)

  9. Percent Change From Baseline for Serum Concentration of s-CTX at Week 78 - PD-TP II Subset

    Serum concentration below the LLoQ was set to the LLoQ. The percent change from baseline for serum concentration at each visit was calculated as (\[Result at each visit - Result at Baseline\] / Result at Baseline) × 100.

    Time frame: Baseline (Week 0 Day 1 predose), Week 78

  10. Percent Change From Baseline for Serum Concentration of Procollagen Type 1 N-terminal Propeptide (P1NP) at Weeks 26 and 52 - PD Set

    Serum concentration below the LLoQ was set to the LLoQ. The percent change from baseline for serum concentration at each visit was calculated as (\[Result at each visit - Result at Baseline\] / Result at Baseline) × 100.

    Time frame: Baseline (Week 0 Day 1 predose), Weeks 26 and 52 (predose)

  11. Percent Change From Baseline for Serum Concentration of P1NP at Week 78 - PD-TP II Subset

    Serum concentration below the LLoQ was set to the LLoQ. The percent change from baseline for serum concentration was calculated as (\[Result at each visit - Result at Baseline\] / Result at Baseline) × 100.

    Time frame: Baseline (Week 0 Day 1 predose), Week 78

  12. Number of Participants With at Least 1 Anti-drug Antibodies (ADA)/Neutralizing Antibodies (NAb) Result After the First Study Drug Administration of TP I - Safety Set

    Samples that were positive in the ADA confirmatory assay were analyzed further to conduct a NAb assessment. The test outcomes for the screening assay were 'Positive' or 'Negative'. The number of patients with at least one ADA/NAb positive result after the first study drug administration of each treatment period including scheduled and unscheduled visits (Treatment Period I: Week 0 / Treatment Period II: Week 52) regardless of their ADA status at baseline were presented.

    Time frame: up to Week 52 predose

  13. Number of Participants With at Least 1 ADA/NAb Result After the First Study Drug Administration of TP II - Safety-TP II Subset

    Samples that were positive in the ADA confirmatory assay were analyzed further to conduct a NAb assessment. The test outcomes for the screening assay were 'Positive' or 'Negative'. The number of patients with at least one ADA/NAb positive result after the first study drug administration of each treatment period including scheduled and unscheduled visits (Treatment Period I: Week 0 / Treatment Period II: Week 52) regardless of their ADA status at baseline were presented.

    Time frame: from Week 52 to Week 78

07

Results

Posted May 16, 2024

Participant flow

The recruitment was conducted in 20 study centers in 4 countries.

TP I - Week 0, Day 1 to Week 52 Predose
Participant flow — TP I - Week 0, Day 1 to Week 52 Predose
MilestoneCT-P41US-licensed ProliaCT-P41 MaintenanceUS-licensed Prolia MaintenanceSwitched to CT-P41
Started240239000
Completed221201000
Not completed1938000
Withdrew: Withdrawal by subject824000
Withdrew: Adverse event45000
Withdrew: Protocol violation54000
Withdrew: Lost to follow-up03000
Withdrew: Physician decision10000
Withdrew: Disease progression01000
Withdrew: Terminated the study before the initiation of the study treatment11000
TP II - Week 52 to Week 78
Participant flow — TP II - Week 52 to Week 78
MilestoneCT-P41US-licensed ProliaCT-P41 MaintenanceUS-licensed Prolia MaintenanceSwitched to CT-P41
Started00221100101
Completed00220100101
Not completed00100
Withdrew: Discontinued the study treatment before the study treatment initiation due to the adverse event00100

Outcome measures

PrimaryPercent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 52 - Full Analysis Set (FAS)

Bone mineral density was assessed by dual-energy X-ray absorptiometry (DXA) and assessments of the lumbar spine (L1 to L4) were performed at a central imaging vendor. To evaluate the difference between 2 groups in the primary efficacy endpoint, the percent change from baseline in BMD for lumbar spine (L1 to L4) by DXA at Week 52 was analyzed using an analysis of covariance (ANCOVA) model coupled with multiple imputation assuming the data to be missing at random (MAR).

Time frame:
baseline (screening), Week 52 predose
Reported as:
Least squares mean · percentage change (%)
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 52 - Full Analysis Set (FAS)
percentage change (%)CT-P41US-licensed Prolia
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 52 - Full Analysis Set (FAS)4.9597 ± 0.299775.1528 ± 0.32133
Statistical analysis
  • CT-P41 vs US-licensed Prolia · ANCOVA · Mean difference (final values): -0.19 · 90% CI -0.76 to 0.38ANCOVA included the treatment as a fixed effect and age, baseline LS-BMD T-score, and prior bisphosphonates therapy (Yes versus No) as covariates.
SecondaryPercent Change From Baseline in Lumbar Spine, Total Hip, and Femoral Neck BMD at Week 52 - FAS

Bone mineral density was assessed by DXA and assessments of the lumbar spine (L1 to L4), total hip, and femoral neck were performed at a central imaging vendor.

Time frame:
baseline (screening), Week 52 predose
Reported as:
Mean · percentage change (%)
Percent Change From Baseline in Lumbar Spine, Total Hip, and Femoral Neck BMD at Week 52 - FAS
percentage change (%)CT-P41US-licensed Prolia
Lumbar spine5.4913 ± 3.799075.6621 ± 3.75768
Total hip2.7914 ± 2.870442.4253 ± 2.84061
Femoral neck2.2295 ± 4.020311.9476 ± 3.86739
SecondaryPercent Change From Baseline in Lumbar Spine, Total Hip, and Femoral Neck BMD at Week 78 - FAS-TP II Subset

Bone mineral density was assessed by DXA and assessments of the lumbar spine (L1 to L4), total hip, and femoral neck BMD were performed at a central imaging vendor.

Time frame:
baseline (screening), Week 78
Reported as:
Mean · percentage change (%)
Percent Change From Baseline in Lumbar Spine, Total Hip, and Femoral Neck BMD at Week 78 - FAS-TP II Subset
percentage change (%)CT-P41 MaintenanceUS-licensed Prolia MaintenanceSwitched to CT-P41
Lumbar spine6.8588 ± 4.127956.5745 ± 3.404377.0532 ± 3.55985
Total hip3.4706 ± 2.810172.7947 ± 2.798623.3837 ± 2.92786
Femoral neck2.9995 ± 3.730722.4429 ± 3.617862.8226 ± 4.02021
SecondaryIncidence of New Vertebral, Nonvertebral, and Hip Fractures During TP I - FAS

Efficacy analysis of new vertebral fractures included only vertebral fractures occurring from T4 to L4 and confirmed by the central imaging vendor. A new vertebral fracture was defined as an increase of ≥1 grade in any vertebra from T4 to L4 that was normal at screening. The nonvertebral fractures endpoint included fractures other than those of the vertebrae, excluding the skull, facial bones, mandible, metacarpals, and phalanges (fingers or toes) since they are not associated with decreased BMD, and excluded pathologic fractures and those associated with severe trauma acquired from a fall (from a height higher than a stool, chair, or first rung of a ladder) or otherwise. Only nonvertebral fractures confirmed by the central imaging vendor were included in the efficacy analysis. The fractures occurring at the site of femur neck, femur intertrochanter, or femur subtrochanter were considered as a hip fracture.

Time frame:
up to Week 52 predose
Reported as:
Count of participants · Participants
Incidence of New Vertebral, Nonvertebral, and Hip Fractures During TP I - FAS
ParticipantsCT-P41US-licensed Prolia
New vertebral fracture11
Nonvertebral fracture24
Hip fracture00
SecondaryIncidence of New Vertebral, Nonvertebral, and Hip Fractures During TP II - FAS-TP II Subset

Efficacy analysis of new vertebral fractures included only vertebral fractures occurring from T4 to L4 and confirmed by the central imaging vendor. A new vertebral fracture was defined as an increase of ≥1 grade in any vertebra from T4 to L4 that was normal at screening. The nonvertebral fractures endpoint included fractures other than those of the vertebrae, excluding the skull, facial bones, mandible, metacarpals, and phalanges (fingers or toes) since they are not associated with decreased BMD, and excluded pathologic fractures and those associated with severe trauma acquired from a fall (from a height higher than a stool, chair, or first rung of a ladder) or otherwise. Only nonvertebral fractures confirmed by the central imaging vendor were included in the efficacy analysis. The fractures occurring at the site of femur neck, femur intertrochanter, or femur subtrochanter were considered as a hip fracture.

Time frame:
from Week 52 to Week 78
Reported as:
Count of participants · Participants
Incidence of New Vertebral, Nonvertebral, and Hip Fractures During TP II - FAS-TP II Subset
ParticipantsCT-P41 MaintenanceUS-licensed Prolia MaintenanceSwitched to CT-P41
New vertebral fracture100
Nonvertebral fracture201
Hip fracture000
SecondaryTrough Serum Concentration (Ctrough) of Denosumab at Weeks 0 and 26 - Pharmacokinetic (PK) Set

The Ctrough, a concentration before the next study drug administration, was calculated by non-compartmental analysis method from the concentration-time data. All serum concentrations below the lower limit of quantification (LLoQ) was set to 0 in the descriptive summaries of PK parameter estimation. In TP I, the Ctrough of denosumab at Weeks 0 and 26 was assessed as the serum concentration at Weeks 26 and 52 before the study drug administration, respectively.

Time frame:
Week 0 Day 1 predose, Week 26 predose
Reported as:
Mean · ng/mL
Trough Serum Concentration (Ctrough) of Denosumab at Weeks 0 and 26 - Pharmacokinetic (PK) Set
ng/mLCT-P41US-licensed Prolia
Week 0 Day 146.79 ± 105.10231.69 ± 73.253
Week 2675.64 ± 154.63063.99 ± 140.912
SecondaryCtrough of Denosumab at Week 52 - PK-TP II Subset

The Ctrough, a concentration before the next study drug administration, was calculated by non-compartmental analysis method from the concentration-time data. All serum concentrations below the LLoQ was set to 0 in the descriptive summaries of PK parameter estimation. In TP II, the Ctrough of denosumab at Week 52 was assessed as the serum concentration at Week 78.

Time frame:
Week 52
Reported as:
Mean · ng/mL
Ctrough of Denosumab at Week 52 - PK-TP II Subset
ng/mLCT-P41 MaintenanceUS-licensed Prolia MaintenanceSwitched to CT-P41
Ctrough of Denosumab at Week 52 - PK-TP II Subset70.24 ± 126.85266.60 ± 129.573126.15 ± 508.689
SecondaryMaximum Serum Concentration (Cmax) of Denosumab After First Dose - PK Set

Cmax was calculated by non-compartmental analysis method from the concentration-time data. All serum concentrations below the LLoQ was set to 0 in the descriptive summaries of PK parameter estimation.

Time frame:
from baseline (Week 0 Day 1 predose) to Week 26 predose
Reported as:
Geometric mean · ng/mL
Maximum Serum Concentration (Cmax) of Denosumab After First Dose - PK Set
ng/mLCT-P41US-licensed Prolia
Maximum Serum Concentration (Cmax) of Denosumab After First Dose - PK Set5851.2 ± 32.25492.7 ± 29.8
SecondaryPercent Change From Baseline for Serum Concentration of Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) at Weeks 26 and 52 - Pharmacodynamic (PD) Set

Serum concentration below the LLoQ was set to the LLoQ. The percent change from baseline for serum concentration at each visit was calculated as (\[Result at each visit - Result at Baseline\] / Result at Baseline) × 100.

Time frame:
Baseline (Week 0 Day 1 predose), Weeks 26 and 52 (predose)
Reported as:
Median · percentage change (%)
Percent Change From Baseline for Serum Concentration of Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) at Weeks 26 and 52 - Pharmacodynamic (PD) Set
percentage change (%)CT-P41US-licensed Prolia
Week 26-75.6972 (-83.7838 to -59.8504)-74.3547 (-81.8667 to -63.0572)
Week 52-72.7506 (-85.8306 to -57.1429)-72.5275 (-82.8794 to -56.6188)
SecondaryPercent Change From Baseline for Serum Concentration of s-CTX at Week 78 - PD-TP II Subset

Serum concentration below the LLoQ was set to the LLoQ. The percent change from baseline for serum concentration at each visit was calculated as (\[Result at each visit - Result at Baseline\] / Result at Baseline) × 100.

Time frame:
Baseline (Week 0 Day 1 predose), Week 78
Reported as:
Median · percentage change (%)
Percent Change From Baseline for Serum Concentration of s-CTX at Week 78 - PD-TP II Subset
percentage change (%)CT-P41 MaintenanceUS-licensed Prolia MaintenanceSwitched to CT-P41
Percent Change From Baseline for Serum Concentration of s-CTX at Week 78 - PD-TP II Subset-70.4609 (-81.0680 to -46.4052)-64.9063 (-78.9644 to -48.6034)-70.1268 (-84.3162 to -47.4940)
SecondaryPercent Change From Baseline for Serum Concentration of Procollagen Type 1 N-terminal Propeptide (P1NP) at Weeks 26 and 52 - PD Set

Serum concentration below the LLoQ was set to the LLoQ. The percent change from baseline for serum concentration at each visit was calculated as (\[Result at each visit - Result at Baseline\] / Result at Baseline) × 100.

Time frame:
Baseline (Week 0 Day 1 predose), Weeks 26 and 52 (predose)
Reported as:
Median · percentage change (%)
Percent Change From Baseline for Serum Concentration of Procollagen Type 1 N-terminal Propeptide (P1NP) at Weeks 26 and 52 - PD Set
percentage change (%)CT-P41US-licensed Prolia
Week 26-69.31 (-76.69 to -57.78)-68.22 (-76.79 to -56.68)
Week 52-69.99 (-76.77 to -50.26)-66.61 (-76.56 to -53.16)
SecondaryPercent Change From Baseline for Serum Concentration of P1NP at Week 78 - PD-TP II Subset

Serum concentration below the LLoQ was set to the LLoQ. The percent change from baseline for serum concentration was calculated as (\[Result at each visit - Result at Baseline\] / Result at Baseline) × 100.

Time frame:
Baseline (Week 0 Day 1 predose), Week 78
Reported as:
Median · percentage change (%)
Percent Change From Baseline for Serum Concentration of P1NP at Week 78 - PD-TP II Subset
percentage change (%)CT-P41 MaintenanceUS-licensed Prolia MaintenanceSwitched to CT-P41
Percent Change From Baseline for Serum Concentration of P1NP at Week 78 - PD-TP II Subset-67.05 (-76.20 to -53.24)-68.60 (-75.12 to -50.11)-64.54 (-78.00 to -53.92)
SecondaryNumber of Participants With at Least 1 Anti-drug Antibodies (ADA)/Neutralizing Antibodies (NAb) Result After the First Study Drug Administration of TP I - Safety Set

Samples that were positive in the ADA confirmatory assay were analyzed further to conduct a NAb assessment. The test outcomes for the screening assay were 'Positive' or 'Negative'. The number of patients with at least one ADA/NAb positive result after the first study drug administration of each treatment period including scheduled and unscheduled visits (Treatment Period I: Week 0 / Treatment Period II: Week 52) regardless of their ADA status at baseline were presented.

Time frame:
up to Week 52 predose
Reported as:
Count of participants · Participants
Number of Participants With at Least 1 Anti-drug Antibodies (ADA)/Neutralizing Antibodies (NAb) Result After the First Study Drug Administration of TP I - Safety Set
ParticipantsCT-P41US-licensed Prolia
ADA positive233234
NAb positive00
SecondaryNumber of Participants With at Least 1 ADA/NAb Result After the First Study Drug Administration of TP II - Safety-TP II Subset

Samples that were positive in the ADA confirmatory assay were analyzed further to conduct a NAb assessment. The test outcomes for the screening assay were 'Positive' or 'Negative'. The number of patients with at least one ADA/NAb positive result after the first study drug administration of each treatment period including scheduled and unscheduled visits (Treatment Period I: Week 0 / Treatment Period II: Week 52) regardless of their ADA status at baseline were presented.

Time frame:
from Week 52 to Week 78
Reported as:
Count of participants · Participants
Number of Participants With at Least 1 ADA/NAb Result After the First Study Drug Administration of TP II - Safety-TP II Subset
ParticipantsCT-P41 MaintenanceUS-licensed Prolia MaintenanceSwitched to CT-P41
ADA positive2089293
NAb positive000

Adverse events

Collected over Through Week 78 - Treatment Period I: Adverse event start date before the study drug administration in Treatment Period II - Treatment Period II: Adverse event start date on or after the date of study drug administration in Treatment Period II.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CT-P411/239 (0.4%)7/239 (2.9%)98/239 (41%)
US-licensed Prolia0/238 (0%)10/238 (4.2%)86/238 (36.1%)
CT-P41 Maintenance1/220 (0.5%)8/220 (3.6%)44/220 (20%)
US-licensed Prolia Maintenance0/100 (0%)3/100 (3%)14/100 (14%)
Switched to CT-P410/101 (0%)0/101 (0%)29/101 (28.7%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventCT-P41US-licensed ProliaCT-P41 MaintenanceUS-licensed Prolia MaintenanceSwitched to CT-P41
CataractEye disorders0/2390/2380/2201/1000/101
Hormone level abnormalInvestigations0/2390/2380/2201/1000/101
Benign neoplasm of adrenal glandNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2390/2380/2201/1000/101
EpistaxisRespiratory, thoracic and mediastinal disorders0/2390/2380/2201/1000/101
Angina unstableCardiac disorders0/2390/2382/2200/1000/101
Gastrointestinal perforationGastrointestinal disorders0/2390/2381/2200/1000/101
Atrial fibrillationCardiac disorders0/2390/2381/2200/1000/101
Acute myocardial infarctionCardiac disorders0/2391/2381/2200/1000/101
ArthritisMusculoskeletal and connective tissue disorders0/2390/2381/2200/1000/101
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2390/2381/2200/1000/101
Most frequent other events
Most frequent other events
EventCT-P41US-licensed ProliaCT-P41 MaintenanceUS-licensed Prolia MaintenanceSwitched to CT-P41
COVID-19Infections and infestations28/23926/2388/2203/1006/101
Upper respiratory tract infectionInfections and infestations25/23920/23813/2204/10011/101
ArthralgiaMusculoskeletal and connective tissue disorders24/23921/2387/2200/1001/101
Vitamin D deficiencyMetabolism and nutrition disorders15/2395/2386/2203/1004/101
OsteoarthritisMusculoskeletal and connective tissue disorders9/23913/2382/2201/1002/101
NasopharyngitisInfections and infestations10/23912/2384/2203/1004/101
Urinary tract infectionInfections and infestations12/2394/2386/2200/1003/101

Baseline characteristics

The overall number of participants analyzed represents the Intent-to-treat (ITT) Set. The ITT set was defined as all participants randomly assigned to receive study drug (CT-P41 or US-Prolia), regardless of whether or not any study drug was administered.

Age, Continuous
Age, Continuous(years)CT-P41US-licensed ProliaTotal
Median66.0 (50 to 79)66.0 (51 to 79)66.0 (50 to 79)
Sex: Female, Male
Sex: Female, Male(Participants)CT-P41US-licensed ProliaTotal
Female240239479
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)CT-P41US-licensed ProliaTotal
Race - White240239479
Ethnicity - Hispanic or Latino033
Ethnicity - Non-Hispanic or Non-Latino240236476
Body mass index
Body mass index(kg/m2)CT-P41US-licensed ProliaTotal
Mean24.92 ± 4.23025.23 ± 4.32825.08 ± 4.277
08

Study locations

20 sites
  • Center For Clinical And Basic Research
    Tallinn, Harjumaa 10128, Estonia
  • East Tallinn Central Hospital-Ravi 18
    Tallinn, Harjumaa 11312, Estonia
  • Clinical Research Centre Ltd
    Tartu, Tartumaa 50106, Estonia
  • KLV Arstikabinet
    Parnu, 80010, Estonia
  • Health Center Association, Medical Center Liepaja
    Liepaja, 3401, Latvia
  • Health Center 4-117 K. Barona Str
    Riga, 1012, Latvia
  • AES - DRS - Synexus Polska Sp. z o.o. Oddzial we Wroclawiu
    Wroclaw, Dolnoslaskie 50-381, Poland
  • SOMED CR Sp. z o.o. Sp. Komandytowa - Lodz
    Lódz, Lódzkie 90-368, Poland
  • Krakowskie Centrum Medyczne
    Kraków, Malopolskie 31-501, Poland
  • AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Warszawie
    Warszawa, Mazowieckie 01-192, Poland
  • SOMED CR Sp. z o.o. Sp. Komandytowa - Warszawa
    Warszawa, Mazowieckie 01-737, Poland
  • NZOZ Osteo Medic SC Artur Racewicz Jerzy Supronik
    Bialystok, Podlaskie 15-351, Poland
  • AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Gdyni
    Gdynia, Pomorskie 81-537, Poland
  • AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Poznaniu
    Poznan, Wielkopolskie 60-702, Poland
  • Centrum Medyczne Poznan - PRATIA - PPDS
    Skórzewo, Wielkopolskie 60-185, Poland
  • MCM Krakow - PRATIA - PPDS
    Kraków, 30-510, Poland
  • AES - AS - Medical Center of Edelweiss Medics LLC
    Kyiv, 02002, Ukraine
  • Clinic of SI Institute of Gerontology n.a. D.F.Chebotaryov of NAMS of Ukraine
    Kyiv, 04114, Ukraine
  • AES - AS - Medical Center of Medbud - Clinic LLC
    Kyiv, Ukraine
  • Clinic of SRI of Invalid Rehab. (ESTC) of VNMU n.a. M.I.Pyrohov
    Vinnytsia, 21029, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in May 2023, 23 months.

Results were first posted in May 2024, 11 months after primary completion.

Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's 23 months is close to that.

Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2021
First posted
Feb 17, 2021
StartActual
Jun 17, 2021
Primary completionActual
May 18, 2023
CompletionActual
Nov 16, 2023
Results first posted
May 16, 2024
Last update
Jun 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04757376
Lead sponsor
Celltrion
Responsible party
Sponsor
First posted
Feb 17, 2021
Start date
Jun 17, 2021
Primary completion
May 18, 2023
Completion
Nov 16, 2023
Results posted
May 16, 2024
Last update
Jun 14, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion